Jury rules Prempro caused woman’s breast cancer

Share this article:
A Philadelphia jury found on Tuesday that Wyeth’s hormone replacement therapy Prempro was the cause of a woman’s breast cancer and awarded her and her husband damages of $3 million. Wyeth said it plans to appeal the decision. “We respectfully disagree that there is any scientific basis to support the jury’s finding of a causal link between Wyeth’s hormone therapies and the plaintiff’s breast cancer,” said Barbara Binis, an attorney representing Wyeth in the case. A previous Philadelphia jury also found in favor of the plaintiff, Jennie Nelson in October. However the judge threw out that verdict and declared a mistrial, leading to the trial that concluded yesterday. The original jury had awarded Nelson and her husband $1.5 million in compensatory damages. This time Nelson was awarded $2.4 million and her husband $600,000. The reason for the mistrial was not disclosed however there has been speculation since that it may have been overturned as a result of juror misconduct. Wyeth is facing approximately 5,000 lawsuits over its hormone replacement therapies. The drugs remain on the market despite a major government-sponsored study that found using them for five years or more can increase the risk of breast cancer.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...